Janux Therapeutics (JANX) to Post Earnings on Thursday

Janux Therapeutics (NASDAQ:JANX) is expected to be posting its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect the company to post earnings of ($0.26) per share and revenue of $19.0750 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Friday, August 14, 2026 at 4:00 PM ET.

Janux Therapeutics (NASDAQ:JANX) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.39) EPS for the quarter, beating the consensus estimate of ($0.52) by $0.13. The firm had revenue of $3.73 million for the quarter, compared to the consensus estimate of $4.36 million. On average, analysts expect Janux Therapeutics to post $-2 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Janux Therapeutics Stock Performance

Shares of Janux Therapeutics stock opened at $15.96 on Wednesday. Janux Therapeutics has a fifty-two week low of $12.12 and a fifty-two week high of $35.34. The company has a market capitalization of $973.24 million, a P/E ratio of -8.67 and a beta of 2.50. The company has a fifty day moving average of $14.96 and a 200 day moving average of $14.40.

Insider Transactions at Janux Therapeutics

In other news, insider Janeen Noel Doyle sold 4,059 shares of the business’s stock in a transaction dated Tuesday, June 2nd. The shares were sold at an average price of $14.03, for a total value of $56,947.77. Following the sale, the insider directly owned 75,941 shares in the company, valued at $1,065,452.23. The trade was a 5.07% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, VP Maria Dobek sold 2,038 shares of the stock in a transaction dated Monday, May 11th. The shares were sold at an average price of $14.17, for a total transaction of $28,878.46. Following the completion of the transaction, the vice president directly owned 32,270 shares of the company’s stock, valued at approximately $457,265.90. The trade was a 5.94% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 7.90% of the company’s stock.

Hedge Funds Weigh In On Janux Therapeutics

Several large investors have recently modified their holdings of the stock. California State Teachers Retirement System lifted its position in Janux Therapeutics by 1.1% in the second quarter. California State Teachers Retirement System now owns 37,139 shares of the company’s stock worth $858,000 after buying an additional 404 shares during the last quarter. Nuveen LLC increased its position in Janux Therapeutics by 0.8% during the fourth quarter. Nuveen LLC now owns 96,416 shares of the company’s stock valued at $1,331,000 after acquiring an additional 787 shares during the last quarter. Kennedy Capital Management LLC raised its stake in shares of Janux Therapeutics by 20.0% in the third quarter. Kennedy Capital Management LLC now owns 11,413 shares of the company’s stock valued at $279,000 after acquiring an additional 1,905 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Janux Therapeutics by 11.5% in the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,866 shares of the company’s stock valued at $551,000 after acquiring an additional 2,463 shares during the period. Finally, Swiss National Bank lifted its holdings in shares of Janux Therapeutics by 3.4% in the 4th quarter. Swiss National Bank now owns 77,100 shares of the company’s stock worth $1,064,000 after acquiring an additional 2,500 shares during the last quarter. Institutional investors own 75.39% of the company’s stock.

Analyst Ratings Changes

JANX has been the subject of a number of recent analyst reports. UBS Group lowered Janux Therapeutics from a “buy” rating to a “neutral” rating and dropped their price objective for the stock from $57.00 to $15.00 in a research note on Wednesday, April 15th. Barclays downgraded Janux Therapeutics from an “overweight” rating to an “underweight” rating and decreased their target price for the company from $29.00 to $14.00 in a research note on Monday, April 20th. Wedbush dropped their price target on Janux Therapeutics from $45.00 to $36.00 and set an “outperform” rating for the company in a research note on Friday, May 8th. Guggenheim reduced their price objective on shares of Janux Therapeutics from $68.00 to $58.00 and set a “buy” rating on the stock in a research report on Friday, May 8th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Janux Therapeutics in a research report on Monday, July 20th. Nine investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, Janux Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $38.08.

Janux Therapeutics Company Profile

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.